Tusamitamab ravtansine, CAS 2254086-60-5

Product Description: Tusamitamab ravtansine (SAR-408701) is a targeted ADC against tumor cells expressing CEACAM5, composed of a humanized anti-CEACAM5 monoclonal antibody covalently linked to the potent cytotoxic agent, maytansinoid DM4 (HY-12454), via a cleavable linker. Tusamitamab ravtansine has an average drug-to-antibody ratio (DAR) of 3.8[1][2][3].

Applications: Cancer-programmed cell death

Formula: N/A

References: [1]Gazzah A, et al. Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody-drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study. Ann Oncol. 2022 Apr;33(4):416-425./[2]Lorenzo Belluomini, et al. Unlocking New Horizons in Small-Cell Lung Cancer Treatment: The Onset of Antibody-Drug Conjugates. Cancers (Basel). 2023 Nov 10;15(22):5368. /[3]Ye-Jin Kim, et al. Chimeric antigen receptor-T cells are effective against CEACAM5 expressing non-small cell lung cancer cells resistant to antibody-drug conjugates. Front Oncol. 2023 Feb 27:13:1124039.

CAS Number: 2254086-60-5

Molecular Weight: 148000 (average)

Compound Purity: 99.42

Research Area: Cancer

Solubility: 10 mM in DMSO

Target: Antibody-Drug Conjugates (ADCs);Microtubule/Tubulin

• Artikelnummer: MEXHY-P99542-1
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-P99542-1
• Green Labware: Nein
• Verpackungseinheit: 1 mg
• Mengeneinheit: STK